Astex Pharmaceuticals to Present AT26893 at EASL

Astex Pharmaceuticals announced it will present data on AT26893, a novel, first-in-class, direct acting antiviral agent against Hepatitis C Virus at the 47th Annual Meeting of the European Association for the Study of the Liver (EASL).
MarketWatch